⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 12, 2023Diabetes Obesity and MetabolismOpen Access

Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT ‐1 trial

Emily R. Hankosky Hui Wang Lisa M. Neff Hong Kan Fangyu Wang Nadia N. Ahmad Adam Stefański W. Timothy Garvey

View Full Paper

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

Tirzepatide treatment significantly reduced the 10-year predicted risk of developing T2D compared with placebo in participants with obesity or overweight, regardless of baseline glycaemic status.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hankosky et al. (2023) studied this question.

synapsesocial.com/papers/69dbc51437b5141e3ba3d36c https://doi.org/10.1111/dom.15269

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year <scp>SURMOUNT</scp>‐1 trial2025 · 17 citations
2Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of <scp>SURMOUNT</scp> ‐ <scp>CN</scp> trialcohort · 2025 · 3 citations
3Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial2024 · 55 citations
4Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspectiveLate-Phase Clinical Trial · 2022 · 121 citations
5Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort StudyCohort Study · 2026 · 1 citations

Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial2025
Efficacy and safety of once‐weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the <scp>SURMOUNT</scp> ‐2 trial2025
Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review2025
Digital Food Purchase Signatures and Their Response to GLP‐1‐Based Treatment in People With ObesityDiabetes Obesity and Metabolism · 2026
Early Treatment Trajectory and Long‐Term Persistence to Semaglutide for Obesity: A Population‐Based Cohort StudyDiabetes Obesity and Metabolism · 2026

More from Diabetes Obesity and Metabolism

More from University of Alabama at Birmingham

More from Eli Lilly (United States)

More from CSL (United States)